REFERENCES
1. Mason M. Getting better at treating prostate cancer: what clinicians should want from scientists. J Cancer Metastasis Treat 2017;3:271-7.
2. Maitland NJ. Getting closer to prostate cancer patients: what scientists should want from clinicians. J Cancer Metastasis Treat 2017;3:262-70.
3. Pippione AC, Boschi D, Pors K, Oliaro-Bosso S, Lolli ML. Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention. J Cancer Metastasis Treat 2017;3:328-61.
4. Morgan R, Pandha HS. HOX transcription factors and the prostate tumor microenvironment. J Cancer Metastasis Treat 2017;3:278-87.
5. Falconer RA, Loadman PM. Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting. J Cancer Metastasis Treat 2017;3:315-27.
6. Shephard AP, Yeung V, Clayton A, Webber JP. Prostate cancer exosomes as modulators of the tumor microenvironment. J Cancer Metastasis Treat 2017;3:288-301.
7. Frame FM, Noble AR, Klein S, Walker HF, Suman R, Kasprowicz R, Mann VM, Simms MS, Maitland NJ. Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer. J Cancer Metastasis Treat 2017;3:302-14.
8. McKenna DJ, Errington R, Pors K. Current challenges and opportunities in treating hypoxic prostate tumors. J Cancer Metastasis Treat 2018;4:11.
